"Concepts and Breakthroughs in Glaucoma" Conference
“青光眼的概念与突破”会议
基本信息
- 批准号:10317233
- 负责人:
- 金额:$ 2.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAdvanced DevelopmentAreaAwardBackBasic ScienceBlindnessCellular biologyClinicalClinical ResearchCollaborationsCountryDevelopmentDiagnosisDiseaseDisease ProgressionEnvironmentEyeFeedbackFellowshipFosteringFoundationsFunctional disorderFundingFutureGlaucomaGoalsHomeostasisIndividualIndustryInstitutionInternationalLearningLocationMentorshipMindMolecularMonitorMorehouse School of MedicineNatural regenerationOphthalmologistOptic DiskParticipantPathogenesisPathologyPatient CarePatientsPhysiologic Intraocular PressurePublic HealthRecording of previous eventsResearchResearch PersonnelReservationsResourcesRetinal Ganglion CellsScientistSecureSenior ScientistSeriesSocietiesStructureStudentsTissuesTranslatingTranslational ResearchTranslationsTravelUnderrepresented PopulationsUniversitiesVisionWomanWorkcareercareer developmentcell injuryeducational atmosphereethnic diversityimaging modalityinterestlecturesmeetingsmemberneuroprotectionnew technologynovelnovel therapeuticspostersrecruitrole modelsymposiumtranslational impact
项目摘要
Summary
This proposal seeks support for students and junior investigators (travel awardees) to attend the 2021 Inter-
national Society for Eye Research (ISER)-BrightFocus Foundation (BFF) glaucoma meeting titled "Concepts
and Breakthroughs in Glaucoma" to be held October 6th-9th, 2021 in Atlanta, Georgia at the Emory Conference
Center and Hotel. As was the case for the 2017 and 2019 meetings, our goal is to bring together basic
scientists, clinician-scientists, students and fellows for presentations and in-depth discussions on recent excit-
ing research advances and developments in molecular mechanisms underlying glaucomatous pathology, in
both the conventional outflow tract and the optic nerve head. Additionally, novel technologies developed: (i) to
diagnose and monitor disease progression, (ii) to modify/restore glaucomatous dysfunction, and (iii) to regen-
erate damaged cells/tissues will be presented. We have already recruited 5 thought leaders in glaucoma to
give keynote lectures at the conference. As with the 2017 and 2019 meetings, the platform sessions will be
selected exclusively from submitted abstracts. We have reserved one platform session for travel awardees
and we are again putting on a one-day "crash course" in glaucoma for people new to glaucoma and stu-
dents/junior investigators, consistent with our goal of increasing participation of young scientists. ISER and
BFF have an established history of promoting diversity, and the selected speakers (from abstracts) will repre-
sent a diverse group of scientists that includes women and members of historically underrepresented groups.
The Specific Aims of the conference are to:
1. Enhance the emerging careers of at least 30 young investigators working in glaucoma research, including
women and members of underrepresented groups, by providing travel awards.
2. Provide a forum for the dissemination of the most recent advances in glaucoma research.
3. Create an environment that will facilitate the exchange of novel ideas among basic and clinician scientists,
and which will generate the opportunity for vision scientists with diverse personal and scientific back-
grounds to meet and establish research collaborations.
4. Bring together scientists working in disparate areas of glaucoma research.
We anticipate that this meeting will provide state-of-the-art information on recent advances in glaucoma and
will serve as an important resource for those involved in the translation of these findings into novel therapeu-
tics. This conference will also provide new opportunities, avenues for new discovery, and a forum to develop
potential collaborations among the attendees. The requested funds will support the travel, accommodation
and registration of 18 students (pre- and postdoctoral) and 12 junior investigators who otherwise would not
have the resources to attend this focused meeting.
总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
W Daniel Stamer其他文献
W Daniel Stamer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('W Daniel Stamer', 18)}}的其他基金
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 2.71万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 2.71万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 2.71万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 2.71万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 2.71万 - 项目类别:














{{item.name}}会员




